指南与共识药物相互作用特殊人群用药

新冠治疗药物研发中血浆及生物基质蛋白结合正确解读的共识

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.
指南 / 共识 · Clin Pharmacol Ther · 2020-11-21

本文为国际研究者共识,指出游离药物理论在抗病毒药物开发中已成熟应用,但尚未常规用于SARS-CoV-2抗病毒药物。强调蛋白结合对候选药物选择至关重要,需以药物特异性方式正确解读,避免低估或高估其后果。

要点

  • 游离药物理论应常规应用于SARS-CoV-2抗病毒药物研发。
  • 蛋白结合解读需药物特异性,避免低估或高估其影响。
  • 可借鉴HIV和丙肝抗病毒药物开发的历史经验。

核心结论

  • 蛋白结合的正确解读对SARS-CoV-2治疗药物候选选择至关重要,需避免低估或高估其后果。

研究设计与样本

  • 国际研究者共识论文,基于历史抗病毒药物开发经验进行论述。

主要发现

  • 游离药物理论在药物开发中已成熟但未常规用于SARS-CoV-2抗病毒药。
  • 蛋白结合广泛影响药代动力学和药效学,需以药物特异性方式解读。

临床怎么用

  • 在SARS-CoV-2候选药物筛选中应纳入蛋白结合评估,并按药物特异性解读。
  • 借鉴HIV和丙肝病毒抗病毒药物开发中应用游离药物理论的经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The urgent global public health need presented by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has brought scientists from diverse backgrounds together in an unprecedented international effort to rapidly identify interventions. There is a pressing need to apply clinical pharmacology principles and this has already been recognized by several other groups. However, one area that warrants additional specific consideration relates to plasma and tissue protein binding that broadly influences pharmacokinetics and pharmacodynamics. The principles of free drug theory have been forged and applied across drug development but are not currently being routinely applied for SARS-CoV-2 antiviral drugs. Consideration of protein binding is of critical importance to candidate selection but requires correct interpretation, in a drug-specific manner, to avoid either underinterpretation or overinterpretation of its consequences. This paper represents a consensus from international researchers seeking to apply historical knowledge, which has underpinned highly successful antiviral drug development for other viruses, such as HIV and hepatitis C virus for decades.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Boffito M, Back DJ, Flexner C, et al. Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development. Clin Pharmacol Ther. 2020. PMID: 33113246. doi:10.1002/cpt.2099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。